PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 30266754-10 2019 HuR-deficient cells were especially sensitive to stress, including low glucose conditions or a mutant IDH1 inhibitor (AGI-5198). AGI-5198 118-126 isocitrate dehydrogenase (NADP(+)) 1 Homo sapiens 102-106 31139406-9 2019 Effects of EGCG in IDH-mutated cell lines were diminished by treatment with the IDH1mut inhibitor AGI-5198. AGI-5198 98-106 isocitrate dehydrogenase (NADP(+)) 1 Homo sapiens 19-22 31160965-5 2019 Methods: Proliferation and clonogenic assays were performed in chondrosarcoma cell lines after gamma-radiation in combination with mutant IDH1 inhibitor AGI-5198. AGI-5198 153-161 isocitrate dehydrogenase (NADP(+)) 1 Homo sapiens 138-142 30156013-10 2018 In addition, AGI-5198, a selective inhibitor of mutant IDH1 partially reversed the decrease in viability after JQ1 treatment and also suppressed the JQ1-induced apoptosis in RBE cells. AGI-5198 13-21 isocitrate dehydrogenase (NADP(+)) 1 Homo sapiens 55-59 29382206-7 2018 In addition, the authors verified the efficacy of the specific mutant IDH1 inhibitor AGI-5198 by tracking the intracellular 2-HG concentration, which decreased in a dose-dependent manner. AGI-5198 85-93 isocitrate dehydrogenase (NADP(+)) 1 Homo sapiens 70-74 29879375-7 2018 These effects were abolished by the IDH1MUT inhibitor AGI-5198 and were restored by treatment with d-2HG. AGI-5198 54-62 isocitrate dehydrogenase (NADP(+)) 1 Homo sapiens 36-43 29366652-2 2018 AGI-5198, a potent and selective inhibitor of the mutant IDH1 enzyme, was radiolabeled with radioiodine and fluorine-18. AGI-5198 0-8 isocitrate dehydrogenase (NADP(+)) 1 Homo sapiens 57-61 26368816-3 2015 The IDH1 inhibitor AGI-5198 abrogates the ability of mutant IDH1 to produce the oncometabolite D-2 hydroxyglutarate (D-2HG) in gliomas. AGI-5198 19-27 isocitrate dehydrogenase (NADP(+)) 1 Homo sapiens 4-8 26363012-0 2015 Radioprotection of IDH1-Mutated Cancer Cells by the IDH1-Mutant Inhibitor AGI-5198. AGI-5198 74-82 isocitrate dehydrogenase (NADP(+)) 1 Homo sapiens 19-23 26363012-0 2015 Radioprotection of IDH1-Mutated Cancer Cells by the IDH1-Mutant Inhibitor AGI-5198. AGI-5198 74-82 isocitrate dehydrogenase (NADP(+)) 1 Homo sapiens 52-56 26363012-4 2015 These effects were reversed by the IDH1(R132H) inhibitor AGI-5198. AGI-5198 57-65 isocitrate dehydrogenase (NADP(+)) 1 Homo sapiens 35-39 26368816-3 2015 The IDH1 inhibitor AGI-5198 abrogates the ability of mutant IDH1 to produce the oncometabolite D-2 hydroxyglutarate (D-2HG) in gliomas. AGI-5198 19-27 isocitrate dehydrogenase (NADP(+)) 1 Homo sapiens 60-64 25980580-9 2015 Moreover, synergistic interactions occurred when metformin treatment was combined with the selective R132H-IDH1 inhibitor AGI-5198. AGI-5198 122-130 isocitrate dehydrogenase (NADP(+)) 1 Homo sapiens 107-111 25778530-8 2015 A human IDH1-R132H-specific inhibitor (AGI-5198) significantly ameliorated both hematopoietic and 2-HG responses in human but not zebrafish IDH1 mutant expression. AGI-5198 39-47 isocitrate dehydrogenase (NADP(+)) 1 Homo sapiens 8-12 23558169-4 2013 A selective R132H-IDH1 inhibitor (AGI-5198) identified through a high-throughput screen blocked, in a dose-dependent manner, the ability of the mutant enzyme (mIDH1) to produce R-2-hydroxyglutarate (R-2HG). AGI-5198 34-42 isocitrate dehydrogenase (NADP(+)) 1 Homo sapiens 18-22